Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression

DOI: 10.1016/j.bbmt.2018.06.010
Biology of Blood and Marrow Transplantation, 2018, 24, 2040-2046.

#	Paper	IF	Citations
24	Highly sensitive chimerism detection in blood is associated with increased risk of relapse after allogeneic hematopoietic cell transplantation in childhood leukemia. *Pediatric Transplantation*, **2019**, 23, e13549	1.8	5
23	Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. *Frontiers in Pediatrics*, **2019**, 7, 412	3.4	12
22	Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. *Cancers*, **2019**, 11,	6.6	4
21	Stem Cells and Tissue Engineering. *Success in Academic Surgery*, **2019**, 181-201	0.1	1
20	Success in Academic Surgery: Basic Science. *Success in Academic Surgery*, **2019**,	0.1	0
19	Monitoring AML Response Using Difference from Normal Flow Cytometry. **2019**, 101-137		0
18	Advances in hematopoietic cell transplant for the treatment of hematologic malignancies. *Current Opinion in Pediatrics*, **2019**, 31, 3-13	3.2	2
17	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 197-203	4.7	7
16	Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms. *Journal of Clinical Medicine*, **2020**, 9,	5.1	4
15	How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. *Blood*, **2020**, 135, 1639-1649	2.2	10
14	Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature. *Blood Reviews*, **2020**, 44, 100673	11.1	4
13	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. *Blood*, **2021**, 137, 983-993	2.2	5
12	Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. *BMC Cancer*, **2021**, 21, 292	4.8	1
11	A Simple-to-Use Nomogram for Predicting Survival in Children with Acute Myeloid Leukemia. *BioMed Research International*, **2021**, 2021, 7264623	3	2
10	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
9	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. *Transplantation and Cellular Therapy*, **2021**, 27, 885-907		0
8	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. *Haematologica*, **2021**, 106, 2588-2597	6.6	4

7	Multivariate Analysis of Immune Reconstitution and Relapse Risk Scoring in Children Receiving Allogeneic Stem Cell Transplantation for Acute Leukemias. *Transplantation Direct*, **2021**, 7, e774	2.3	0
6	Measurable Residual Disease in High-Risk Acute Myeloid Leukemia.. *Cancers*, **2022**, 14,	6.6	0
5	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. *Transplantation and Cellular Therapy*, **2022**,		
4	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. *Cancers*, **2022**, 14, 3307	6.6	
3	MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?. **2022**, 14, 4294		0
2	Bone marrow transplant for the patient with primary immune deficiency disorder. **2022**, 1479-1504		0
1	Highly-sensitive chimerism analysis in blood after allogeneic hematopoietic cell transplantation in childhood leukemia: Results from the Nordic Microchimerism Study. 2,		0